Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
This manuscript was prepared according to the International Society for Medical Publication Professionals Good Publication Practice for Communicating Company-Sponsored Medical Research: the GPP3 Guidelines
Inject at the start of a planned eating day so the post-injection period aligns with your most structured nutritional intake
The risk of hypoglycemia deserves particular attention
placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in FDA Approves Boehringer Ingelheims JASCAYD (nerandomilast) for IPF The U.S
.png)
US$ 20.19
US$ 29.62
US$ 24.89
.jpg)